Dicerna Pharmaceuticals, Inc. logo
Dicerna Pharmaceuticals, Inc. DRNA

Dicerna Pharmaceuticals, Inc. Income Statement 2011-2026 | DRNA

Annual Income Statement Dicerna Pharmaceuticals, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.67 B 1.33 B 559 M 211 M 53.9 M 133 M 343 M 765 M - -

Shares

74.5 M 68.4 M 55.6 M 21.9 M 20.7 M 20.3 M 16.1 M 16.6 M - -

Net Income

-113 M -120 M -88.9 M -60 M -59.5 M -62.8 M -47.9 M -18.5 M -10.1 M -8.56 M

Revenue

164 M 23.9 M 6.18 M 2.28 M 295 K 184 K - - 7.02 M 7.91 M

EBITDA

-111 M -127 M -60.4 M -59.8 M -58.9 M -62.3 M -44.3 M -16.9 M -8.7 M -7.14 M

Operating Expenses

278 M 152 M 67.4 M 62.9 M 60 M 63.2 M 45.1 M - - -

General and Administrative Expenses

72.1 M 42.8 M 21.7 M 25.9 M 18.3 M 19.2 M 15.6 M 5.82 M 4.7 M 4.82 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Dicerna Pharmaceuticals, Inc. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 9.13 -0.76 % $ 591 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.91 2.42 % $ 6.69 M chinaChina
Edesa Biotech Edesa Biotech
EDSA
$ 15.52 -2.39 % $ 49.6 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.47 1.19 % $ 3.72 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 2.24 0.9 % $ 62.5 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
$ 2.26 0.22 % $ 144 M usaUSA
Galapagos NV Galapagos NV
GLPG
$ 28.07 0.75 % $ 2.69 B belgiumBelgium
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.2 3.6 % $ 6.83 B spainSpain
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 31.01 -0.13 % $ 1.78 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 8.44 - $ 76.2 M usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.95 -1.77 % $ 152 M germanyGermany
Immuron Limited Immuron Limited
IMRN
$ 0.83 3.44 % $ 6.55 M australiaAustralia
Incyte Corporation Incyte Corporation
INCY
$ 98.87 -0.23 % $ 19.3 B usaUSA
InMed Pharmaceuticals InMed Pharmaceuticals
INM
$ 0.71 1.28 % $ 1.74 M canadaCanada
INmune Bio INmune Bio
INMB
$ 1.35 1.5 % $ 33.4 M usaUSA
Innoviva Innoviva
INVA
$ 23.13 0.35 % $ 1.56 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 104.54 2.92 % $ 27.2 B germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Jaguar Health Jaguar Health
JAGX
$ 7.55 -4.13 % $ 17.6 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
$ 26.67 -0.02 % $ 1.44 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.43 -4.03 % $ 235 M franceFrance
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.15 0.49 % $ 260 M israelIsrael
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 13.24 6.56 % $ 1.75 B australiaAustralia
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 223.98 -0.39 % $ 4.1 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.22 7.69 % $ 5.3 M israelIsrael
Liquidia Corporation Liquidia Corporation
LQDA
$ 38.39 0.62 % $ 3.3 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.08 0.74 % $ 436 M usaUSA